News
View the latest company news, press releases, and FDA clearances to see exciting milestones at Acuitive Technologies.
Press Releases
Forlenza and Fischetti Join Acuitive Technologies BOD
ALLENDALE, NJ., March 2023
March 23, 2023 (Orthopedics This Week) -- Acuitive Technologies, a medical device manufacturer committed to orthopedic surgery, has welcomed Vince Forlenza and Gary Fischetti to the Acuitive Technologies Board of Directors. Forlenza and Fischetti have decades of experience in medical technology. This will benefit Acuitive Technologies as it focuses on the growth of CITREGEN®. Per the press release, CITREGEN is the “only synthetic, metabolically active resorbable biomaterial that stimulates the natural host tissue healing process and eliminates the inflammatory response seen with many current biodegradable materials.”
Two Industry Veterans Join Acuitive Technologies, Inc. Board of Directors as Independent Members
ALLENDALE, NJ., March 2023
March 13, 2023 (GLOBE NEWSWIRE) -- Acuitive Technologies announced that Vince Forlenza and Gary Fischetti will join their Board of Directors. Both bring decades of medical technology experience and long track records of success. “We are honored these highly successful corporate leaders share our vision and enthusiasm and are willing to provide their guidance to help us deliver a truly market disruptive bio-regenerative platform for the benefit of patients,” said Alex Khowaylo, Acuitive’s Chairman of the Board. “We will benefit immediately from their insight and leadership as we move into our growth stage.”
The 2022 Society for Biomaterials' Technology Innovation and Development Award goes to Dr. Guillermo Ameer and the Acuitive Technologies Team
BALTIMORE, MD., May 2022
It all started with a vision by Northwestern's Dr. Guillermo A. Ameer, Daniel Hale Williams Professor of Biomedical Engineering at the McCormick School of Engineering and Surgery at the Feinberg School of Medicine, who has been awarded the 2022 Technology Innovation and Development Award by the Society for Biomaterials. This award recognizes an individual or team's successful application of basic and applied biomaterials research in the development of a novel medical product or technology that significantly benefits the health and well-being of patients.
Biomaterial Technology Moves from Lab Bench to the Orthopedic Market
EVANSTON, IL., December 2021
Northwestern biomedical engineer Guillermo A. Ameer has achieved a rare, major accomplishment: A medical product based on novel biomaterials pioneered in his laboratory will be widely available for use in musculoskeletal surgeries to directly benefit patients. The biomaterial technology, called CITREGEN®, developed by the startup company Acuitive Technologies Inc., is featured in Stryker Corporation’s CITRELOCK®, an innovative device that debuted in September.
Acuitive Technologies Enters Sport Medicine Market - CITRESPLINE™ & CITRELOCK®
ALLENDALE, NJ., March 4th, 2021
Acuitive Technologies Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITRESPLINE and CITRELOCK® Ligament Reconstruction Devices using their patented CITREGEN® biomaterial technology, a market disruptive bioresorbable synthetic polymer.
Acuitive Technologies Granted FDA 510(k) Clearance for CITREFIX™ Knotless Suture Anchor
ALLENDALE, NJ., February 11th, 2021
Acuitive Technologies today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITREFIX™ Knotless Suture Anchor System with CITREGEN® material technology, a new generation bioresorbable synthetic polymer.
Acuitive Technologies Granted FDA 510(k) Clearance for CITREGEN® CITRELOCK® Tendon Interference Screw System
ALLENDALE, NJ., October 21st, 2020
Acuitive Technologies today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the CITRELOCK Interference Screw System with CITREGEN material technology, a new generation thermoset bioresorbable synthetic polymer now FDA cleared.
Company News
Ameer Wins 2022 Innovation Commercialization Award
TORONTO, CANADA, July 2022
Northwestern Engineering’s Guillermo A. Ameer was honored with the 2022 Innovation/Commercialization Award by the Tissue Engineering and Regenerative Medicine International Society-Americas (TERMIS-AM). The award recognizes the application of tissue engineering and regenerative medicine in the production of a product or technology that ultimately will benefit patients.
Dr. Michael A. Kelly, MD Obituary
FRANKLIN LAKES, NJ., October 10th, 2022
Kelly, Michael A. M.D., age 70 of Franklin Lakes, passed away on Monday, October 10, 2022. Born in Washington D.C. to Jacques Michael and Ann Muse Gillespie Kelly. He was raised in Plainfield, NJ before moving back to Washington D.C. He attended Gonzaga College High School, the University of North Carolina at Chapel Hill, and Georgetown University Medical School. He did his surgical internship and residency at St. Vincent’s Hospital, his orthopaedic surgery training at Columbia Presbyterian Medical Center, and a fellowship in knee surgery at the Hospital for Special Surgery in NYC under Dr. John Insall.
Guillermo A. Ameer Elected to National Academy of Medicine
EVANSTON, IL., October 18th, 2021
Northwestern Engineering’s Guillermo A. Ameer was one of three University faculty elected to the National Academy of Medicine (NAM). Ameer is the Daniel Hale Williams Professor of Biomedical Engineering in the McCormick School of Engineering and a professor of surgery in Northwestern’s Feinberg School of Medicine, and also the founding director of Northwestern’s Center for Advanced Regenerative Engineering. He is director of the recently established Regenerative Engineering Training Program at the McCormick School of Engineering, supported by the National Institutes of Health.
Acuitive Technologies Collaborates with Ireland-Based Research Institute, CÚRAM
GALWAY, IRELAND
Through their collaboration with CÚRAM, Acuitive Technologies Inc. has demonstrated the scientific potential of their paradigm-changing bioactive CITREGEN™ platform technology to expedite tissue healing and mitigate the problems associated with currently marketed biodegradable devices for numerous musculoskeletal applications
